Phase I safety and efficacy of brenetafusp, a PRAME x CD3 ImmTAC T cell engager, in platinum resistant ovarian cancer (PROC) Meeting Abstract
| Authors: | Friedman, C.; De Burgh Williams, A.; Lopez, J. S.; Ouali, K.; Middleton, M. R.; Thistlethwaite, F.; Hamid, O.; Izar, B.; Moreno Garcia, V.; Johnson, M. L.; Davar, D.; Martin-Liberal, J.; Roxburgh, P.; Moore, K. N.; Olson, D.; Rottey, S.; Kirk, P. B.; Yuan, Y.; Marshall, S.; Yeku, O. |
| Abstract Title: | Phase I safety and efficacy of brenetafusp, a PRAME x CD3 ImmTAC T cell engager, in platinum resistant ovarian cancer (PROC) |
| Meeting Title: | ESMO Congress 2024 |
| Journal Title: | Annals of Oncology |
| Volume: | 35 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2024 Sep 13-17 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-09-01 |
| Start Page: | S569 |
| End Page: | S570 |
| Language: | English |
| ACCESSION: | WOS:001326612901056 |
| DOI: | 10.1016/j.annonc.2024.08.811 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 750P -- Source: Wos |
